SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

tobevibart

VIR·Vir Biotechnology, Inc.
BULLISH
Drug Impact Rating8/10
Trial phase
Phase 3
Time to market
If ECLIPSE 1 data is positive, Vir could file for regulatory approval in 2027, with potential FDA decision in 2028. The program has FDA Breakthrough Therapy and EMA PRIME designations, which could accelerate review.
Why 8/10
The single next hard, dated catalyst is the Phase 3 ECLIPSE 1 topline data presentation at AASLD on November 8, 2026 (tomorrow), with an investor call on November 9. This is a pivotal readout for Vir's lead hepatitis delta program, which drives most of the company's near-term valuation. The company also has an oncology pipeline and Gilead collaboration, so it is not a pure single-asset binary, but the hepatitis delta program is clearly the dominant value driver.
Actionable Insight BULLISH

The pivotal Phase 3 ECLIPSE 1 topline data is being presented at AASLD on November 8, 2026 (tomorrow), with an investor call on November 9 at 8:30 AM ET. Positive results showing non-inferiority or superiority versus bulevirtide/deferred treatment could drive significant upside given the $21 mean analyst price target (90%+ implied upside). Negative or mixed data would likely pressure the stock given the program's centrality to Vir's valuation. ECLIPSE 2 and ECLIPSE 3 readouts are expected in Q1 2027.

Price Chart

Loading chart...

Executive Summary

Tobevibart (VIR-3434) is Vir Biotechnology's investigational monoclonal antibody targeting hepatitis B surface antigen (HBsAg), being developed in combination with elebsiran (VIR-2218, an siRNA) primarily for chronic hepatitis delta (CHD). Phase 2 SOLSTICE data published in NEJM showed 66% of patients achieved undetectable HDV RNA at week 48 with a favorable safety profile. The pivotal Phase 3 ECLIPSE 1 topline results are being presented as a late-breaking oral at AASLD on November 8, 2026, with an investor call on November 9. Gilead's Hepcludex (bulevirtide) was FDA-approved in May 2026 as the first CHD treatment, creating a competitive landscape, but tobevibart+elebsiran offers a potentially more convenient monthly subcutaneous regimen versus daily injections. Vir ended Q3 2026 with ~$901M in cash (plus $90M Gilead upfront), funding operations into H2 2028.

How It Works

Tobevibart is a lab-made antibody that grabs onto a protein (HBsAg) on the surface of hepatitis B and hepatitis delta viruses. This blocks the viruses from entering liver cells and helps the immune system clear viral particles from the blood. It is given as a monthly shot under the skin and is paired with elebsiran, an RNA-targeting drug that silences viral protein production.

Trial Status

The pivotal Phase 3 ECLIPSE 1 trial (NCT06903338, 124 patients enrolled) evaluating tobevibart + elebsiran versus deferred treatment in chronic hepatitis delta has completed enrollment and topline primary endpoint results are being presented at AASLD on November 8, 2026. Two additional Phase 3 trials are ongoing: ECLIPSE 2 (switch study in patients not suppressed on bulevirtide) and ECLIPSE 3 (head-to-head versus bulevirtide), with data expected in Q1 2027. Phase 2 SOLSTICE data published in NEJM showed 66% of combination patients achieved undetectable HDV RNA at week 48 with no grade 3+ treatment-related adverse events.

The Two-Sided Case

▲ Bull Case6
Phase 2 SOLSTICE data showed 66% of combination patients achieved undetectable HDV RNA at week 48 with no grade 3+ treatment-related adverse events, published in NEJM
Monthly subcutaneous dosing offers a significant convenience advantage over Gilead's Hepcludex (bulevirtide), which requires daily injections
FDA Breakthrough Therapy and EMA PRIME designations signal regulatory interest and could accelerate review
Analyst consensus is Strong Buy (12 Buy/Strong Buy, 1 Hold) with a mean price target of $21, implying ~90% upside from the $11.02 close
Strong institutional backing: BlackRock ($211M), Vanguard ($117M), State Street ($102M) are top holders; Point72 doubled its position in Q2 2026
Cash position of ~$901M plus $90M Gilead upfront provides runway into H2 2028, reducing dilution risk
▼ Bear Case5
Gilead's Hepcludex (bulevirtide) was FDA-approved in May 2026 as the first CHD treatment, establishing an incumbent therapy and potentially limiting tobevibart's addressable market
Elevated short-sale volume (z-score 2.02 vs own history) and insider sales by the General Counsel (under 10b5-1 plan) suggest some near-term skepticism
ECLIPSE 1 is an open-label trial versus deferred treatment, not a blinded placebo-controlled design, which may raise questions about the data quality
Vir has no approved products and is pre-revenue; Q3 2026 revenue was -$188K with a net loss of $96.3M
Several institutional holders trimmed or exited positions in Q2 2026, including Citadel (-52.8%), Millennium (-90.2%), and Jacobs Levy (-90.5%)

Upcoming Catalysts

  • Phase 3 ECLIPSE 1 topline data presentation at AASLD on November 8, 2026
  • Investor conference call on November 9, 2026 at 8:30 AM ET
  • ECLIPSE 2 and ECLIPSE 3 Phase 3 readouts expected in Q1 2027
  • Potential regulatory submission if ECLIPSE data is positive

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Vir Biotechnology, Inc. 8-K VIR ·Originating report

Sources · 10

Hover a chip for the title
1 investors.vir.bio2 nejm.org3 investors.vir.bio4 businesswire.com5 fda.gov6 clinicaltrials.gov7 investors.vir.bio8 businesswire.com9 go.drugbank.com10 investors.vir.bio